** Shares of drugmaker Emergent BioSolutions EBS.N fall 3% to $5.60, hit nine-month low
** India's Syngene International SYNN.NS says it has acquired its first biologics facility in the U.S. from Emergent Manufacturing Operations Baltimore, a unit of EBS, for $36.5 million
** The deal is expected to close in March, 2025
** Co says the facility is expected to be operational for client projects from the H2 2025
** Up to last close, EBS has risen more than double in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。